1. Veselkova I. N., Zemljanova E. V. Health problems and medical and social services for the elderly. Psychology of adulthood and aging. 2000; 1:76–88. (Веселкова И. Н., Землянова Е. В. Проблемы здоровья и медико-социального обслуживания пожилых людей. Психология зрелости и старения. 2000; 1:76–88).
2. Sundquist J., Winkleby M. A., Pudaric S. Cardiovascular disease risk factors among older black, Mexican-American and white women and men: an analysis of NHANES III, 1988–1994. Third National Health and Nutrition Examination Survey. J Am Geriatr Soc 2001; 49 (2):109–16.
3. Lewington S., Clarke R., Qizilbash N. et al. Age-specific relevance of usual blood pressure to vascular mortality. Lancet 2002; 360:1903–13.
4. Chazova I. E., Ratova L. G., Bojcov S. A. et al. Diagnosis and treatment of hypertension. Russian recommendations (fourth revision). Systemic hypertension, 2010; 3:5–26. (Чазова И. Е., Ратова Л. Г., Бойцов С. А. и др. Диагностика и лечение артериальной гипертензии. Российские рекомендации (четвертый пересмотр). Системные гипертензии 2010; 3:5–26.
5. Appel L. J., Espeland M., Whelton P. K., et al. Trial of Nonpharmacologic Intervention in the Elderly (TONE). Design and rationale of a blood pressure control trial. Ann Epidemiol. 1995 Mar; 5 (2):119–29.
6. James J DiNicolantonio. Hydrochlorothiazide: is it a wise choice? Expert Opin. Pharmacother. 2012 Apr; 13 (6):807–14.
7. Baguet J. P., Legallicier B., Auquier P. et al. Updated Meta-Analytical Approach to the Efficacy of Antihypertensive Drugs in Reducing Blood Pressure. Clin Drug Invest 2007; 27 (11):734–52.
8. London G., Schmieder R., Calvo C., et al. Indapamide SR versus candesartan and amlodipine in hypertension: the X–CELLENT Study. Am J Hypertens. 2006 Jan; 19 (1):113–21.
9. Bejot Y, et al. Cerebrovasc. Dis. 2010; 29:111–121.
10. Liu L., Wang Z., Gong L., et al. Blood pressure reduction for the secondary prevention of stroke: a Chinese trial and a systematic review of the literature. Hypertens. Res. 2009; 32, 11:1032–40.
11. Nigel S., Beckett M. B., Ch B., et al. Treatment of Hypertension in Patients 80 Years of Age or Older. N Engl J Med 2008; 358:1887–98.
12. Rothwell P. M. Limitations of the usual blood-pressure hypothesis and importance of variability, instability, and episodic hypertension. Lancet 2010; 375:938–48
13. Gosse Ph., Sheridan D., Zannad F., et al. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg: the LIVE Study. J. Hypertens. 2000; 18:1465–75.
14. Henry R. M., Kostense P. J., Bos G., et al. Mild renal insufficiency is associated with increased cardiovascular mortality: The Hoorn study. Kidney int. 2002; 62:1402–7.
15. Marre M., Garcia-Puig J., Kokot F., et al. Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR study. J. Hypertens. 2004; 22:1613–22.
16. ADVANCE Management Committee Study rationale and design of ADVANCE: Action in Diabetes and Vascular disease: preterax and diamicron MR controlled evaluation. Diabetologia 2001; 44:1118–20.
17. Marre M., Garcia-Puig J., Kokot F., et al. Efficacy of indapamide SR compared with enalapril in elderly hypertensive patients with type 2 diabetes. Amer. J. Hypertens. 2007; 20:90–7.
18. Hiddo J., Heerspink L., Ninomiya T., et al. Effects of a fixed combination of perindopril and indapamide in patients with type 2 diabetes and chronic kidney disease. Eur.Heart J. 2010; 31:2888–96.
19. Weidmann P. Metabolic profile of indapamide sustained-release in patients with hypertension. Drugs Safety. 2001; 24:1155–65.
20. Leonetti G., Emeriau J-P., Knauf H., et al. Evaluation of long-term efficacy and acceptability of indapamide SR in elderly hypertensive patients. Current Medical Research and Opinion. 2005; 21:37–46.
